Surgical Outcome of Ahmed Valve Implantation in Mexican Patients with Neovascular Glaucoma

Hernández-Oteyza, Alejandra; Lazcano‐Gomez, Gabriel; Jiménez-Román, Jesús; Hernández-Garciadiego, Carlos

doi:10.5005/jp-journals-10008-1168

Cited by 14 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yalvac reported 63.2 and 56.2 % of success rates at 1 and 2 years after Ahmed glaucoma valve implantation, respectively [72]. Hernandez-Oteyza recently reported a success rate of 60 % at 1 year of follow-up and found that a hypertensive phase in the postoperative period and a worse preoperative BCVA to be risk factors for Ahmed valve surgical failure in patients with NVG [73]. Netland et al found that the success rate was significantly lower over time in eyes with NVG compared with controls.…”

Section: Introductionmentioning

confidence: 99%

Neovascular glaucoma: a review

et al. 2016

View full text Add to dashboard Cite

Neovascular glaucoma (NVG) is a secondary glaucoma generally associated with poor visual prognosis. The development of new vessels over the iris and the iridocorneal angle can obstruct aqueous humor outflow and lead to increased intraocular pressure. The underlying pathogenesis in most cases is posterior segment ischemia, which is most commonly secondary to proliferative diabetic retinopathy or central vein retinal occlusion. The neovascularization process in the eye is driven by the events that alter the homeostatic balance between pro-angiogenic factors, such as the vascular endothelial growth factor and anti-angiogenic factors, such as the pigment-epithelium-derived factor. Early diagnosis of this condition through slit lamp examination of the iris, iridocorneal angle and retina can help to avoid the development of goniosynechia and obstruction of aqueous humor outflow, with consequent intraocular pressure elevation. Historically, NVG treatment was focused on reducing the posterior segment ischemic process that caused the formation of new vessels, through panretinal photocoagulation. Recently, several studies have investigated the application of intravitreal anti-VEGF therapies in NVG. If clinical treatment with the use of hypotensive topical drops is not sufficient, laser and/or surgical procedures are required for intraocular pressure control.

show abstract

Section: Introductionmentioning

confidence: 99%

Neovascular glaucoma: a review

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Yalvac et al [77] reported a success rate of 63.2 and 56.2 % at 1 and 2 years after Ahmedʼs glaucoma valve surgery, respectively. Hernandez-Oteyza et al [78] showed a success rate of 60 % at the 1-year follow-up, indicating that a hypertensive phase in the postoperative period and a lower preoperative BCVA are risk factors for surgical failure in this group of patients [78]. The success rate over time was found to be substantially lower in eyes with NVG compared with controls.…”

Section: Trabeculectomy (Trab)mentioning

confidence: 89%

Neovascular Glaucoma: An Update

Kalogeropoulos

Moussa

Sung

et al. 2022

Klin Monbl Augenheilkd

View full text Add to dashboard Cite

Neovascular glaucoma (NVG) is a severe type of secondary glaucoma with devastating complications and generally poor visual prognosis. NVG is defined by the development of pathological neovessels over the iris and the iridocorneal angle that can block the outflow of aqueous humor, causing elevation of intraocular pressure (IOP). The pathogenesis of NVG is, in most cases, associated with ischemia of the posterior segment, which is most frequently associated with proliferative diabetic retinopathy or central retinal vein occlusion. The advanced stages of NVG are by iris and angle neovascularization, angle, and extremely high IOP, accompanied by ocular pain and poor vision. The therapeutic approach of NVG is based on the reduction of retinal ischemia by panretinal photocoagulation. Intravitreal anti-VEGF administration can contribute to the regression of neovascularization, and topical and systemic medications may be necessary for IOP control. However, if medical treatment with these agents is not enough, surgical procedures may be required to lower IOP and prevent glaucomatous optic neuropathy. Early and prompt diagnosis, with identification of the underlying etiology, can improve IOP control and final visual outcome. The aim of this study is to review current knowledge of the pathogenesis and management of NVG.

show abstract

“…A retrospective analysis of Ahmed GDIs showed that NVG eyes had a significantly lower rate of complete success compared with control eyes without neovascularization at both 1 year (73.3% vs. 89.2%, respectively) and 5 years (20.6% vs. 81.8%, respectively) of follow-up 64 . Similarly, a retrospective review of NVG eyes that underwent Ahmed tube shunts reported an overall success rate of 60.0% at 1 year and found that a postoperative hypertensive phase was correlated with a higher risk of failure 69 . In addition, a prospective study of NVG eyes who underwent placement of a Molteno GDI demonstrated relatively poor rates of IOP control, with success rates of 72.0% at 1 year and 40.0% at 5 years, regardless of the use of adjunctive medications 65 .…”

Section: Surgical Management Of Nvgmentioning

confidence: 96%

“…64 Similarly, a retrospective review of NVG eyes that underwent Ahmed tube shunts reported an overall success rate of 60.0% at 1 year and found that a postoperative hypertensive phase was correlated with a higher risk of failure. 69 In addition, a prospective study of NVG eyes who underwent placement of a Molteno GDI demonstrated relatively poor rates of IOP control, with success rates of 72.0% at 1 year and 40.0% at 5 years, regardless of the use of adjunctive medications. 65 Another retrospective study evaluating the use of Molteno GDIs in NVG eyes found similar success rates of 62.1% at 1 year, 43.1% at 3 years, and 10.3% at 5 years of follow-up.…”

Section: Glaucoma Drainage Implants (Gdis)mentioning

confidence: 99%